Johnston S C, Colford J M, Gress D R
Department of Neurology, University of California, San Francisco 94143-0114, USA.
Neurology. 1998 Aug;51(2):411-8. doi: 10.1212/wnl.51.2.411.
The objective of this study is to estimate the risk of subarachnoid hemorrhage produced by oral contraceptive use.
Studies published since 1960 were identified using MEDLINE, Cumulated Index Medicus, Dissertation Abstracts On-line, and bibliographies of pertinent articles. Two independent reviewers screened published cohort and case-control studies that evaluated the risk of subarachnoid hemorrhage associated with oral contraceptives. Eleven of 21 pertinent studies met predefined quality criteria for inclusion in the meta-analysis. Relative risk (RR) estimations evaluating subarachnoid hemorrhage risk in oral contraceptive users compared with nonusers were extracted from each study by two independent reviewers. Study heterogeneity was assessed by design type, outcome measure (mortality versus incidence), exposure measure (current versus ever use), prevailing estrogen dose used, and control for smoking and hypertension.
The overall summary RR of subarachnoid hemorrhage due to oral contraceptive use was 1.42 (95% CI, 1.12 to 1.80; p = 0.004). When the two study results failing to control for smoking were excluded from the analysis, a slightly greater effect was seen, with an RR of 1.55 (95% CI, 1.26 to 1.91; p < 0.0001). In the six studies controlling for smoking and hypertension the RR was 1.49 (95% CI, 1.20 to 1.85; p = 0.0003). High-estrogen oral contraceptives appeared to impart a greater risk than low-dose preparations in studies controlling for smoking, but the difference was not significant (high-dose RR, 1.94; 95% CI, 1.06 to 3.56; low-dose RR, 1.51; 95% CI, 1.18 to 1.92).
This meta-analysis of observational studies suggests that oral contraceptive use produces a small increase in the risk of subarachnoid hemorrhage.
本研究的目的是评估口服避孕药导致蛛网膜下腔出血的风险。
利用医学在线数据库(MEDLINE)、医学累积索引(Cumulated Index Medicus)、在线论文摘要数据库(Dissertation Abstracts On-line)以及相关文章的参考文献,检索自1960年以来发表的研究。两名独立的评审人员筛选已发表的队列研究和病例对照研究,这些研究评估了与口服避孕药相关的蛛网膜下腔出血风险。21项相关研究中有11项符合纳入荟萃分析的预定义质量标准。两名独立的评审人员从每项研究中提取评估口服避孕药使用者与非使用者相比蛛网膜下腔出血风险的相对风险(RR)估计值。通过设计类型、结局指标(死亡率与发病率)、暴露指标(当前使用与曾经使用)、使用的主要雌激素剂量以及对吸烟和高血压的控制情况来评估研究的异质性。
口服避孕药导致蛛网膜下腔出血的总体汇总RR为1.42(95%CI,1.12至1.80;p = 0.004)。当分析中排除两项未控制吸烟因素的研究结果时,观察到的效应略大,RR为1.55(95%CI,1.26至1.91;p < 0.0001)。在六项控制了吸烟和高血压的研究中,RR为1.49(95%CI,1.20至1.85;p = 0.0003)。在控制吸烟的研究中,高雌激素口服避孕药似乎比低剂量制剂带来更大的风险,但差异不显著(高剂量RR,1.94;95%CI,1.06至3.56;低剂量RR,1.51;95%CI,1.18至1.92)。
这项对观察性研究的荟萃分析表明,口服避孕药会使蛛网膜下腔出血的风险略有增加。